Skip to main content

Table 9 The PatchDock docking analysis between NS5A and NS5B proteins and the approved HCV inhibitors (according atomic contact energy)

From: First report on molecular docking analysis and drug resistance substitutions to approved HCV NS5A and NS5B inhibitors amongst Iranian patients

Proteins HCV inhibitors
Daclatasvir Elbasvir Ledipasvir Ombitasvir Dasabuvir Sofosbuvir
NS5A 1a  − 153.79  − 395.54  − 415.40  − 455.13   
NS5A 1a
(Mutant GLU181)
 − 114.63   
NS5A 3a  − 306.60  − 91.09  − 298.97  − 460.31   
NS5B 1a       − 178.73  − 250.39
NS5B 3a       − 101.30  − 250.39